证券时报·数据宝统计，截至（9月4日）收盘，沪指报3765.88点，跌47.68点，跌幅为1.25%；深成指报 12118.70点，跌353.29点，跌幅为2.83%；创业板指报2776.25点，跌123.12点，跌幅为4.25%。个股方 面，今日91只A股换手率超过20%，其中，中科美菱、三维通信等3只个股换手率达五成以上，半数筹 码易主。（数据宝） | 920108 | 宏海科技 | 18.38 | 23.01 | 6.24 | | --- | --- | --- | --- | --- | | 301590 | 优优绿能 | 170.42 | 22.98 | -5.69 | | 002210 | 飞马国际 | 3.96 | 22.71 | -6.16 | | 603004 | 鼎龙科技 | 23.95 | 22.57 | 1.66 | | 002796 | 世嘉科技 | 15.20 | 22.51 | 3.26 | | 300945 | 曼卡龙 | 23.12 | 22.43 | 5.09 | | 300007 | 汉威科技 | 49.55 | 22.37 | -2.08 | | 600749 | 西藏 ...

证券时报·数据宝统计，截至（9月1日）收盘，沪指报3875.53点，涨17.60点，涨幅为0.46%；深成指报 12828.95点，涨132.80点，涨幅为1.05%；创业板指报2956.37点，涨66.25点，涨幅为2.29%。个股方 面，今日80只A股换手率超过20%，其中，三维通信、北方长龙等2只个股换手率达五成以上，半数筹 码易主。（数据宝） 9月1日两市换手率居前个股一览 | 证券代码 | 证券简称 | 收盘价（元） | 换手率（%） | 涨跌幅（%） | | --- | --- | --- | --- | --- | | 002115 | 三维通信 | 11.52 | 54.64 | 10.03 | | 301357 | 北方长龙 | 180.11 | 54.55 | -1.13 | | 301488 | 豪恩汽电 | 117.00 | 42.96 | -4.92 | | 301378 | 通达海 | 35.93 | 42.87 | -6.68 | | 300139 | 晓程科技 | 22.38 | 41.52 | 13.43 | | 831906 | 舜宇精工 | 33.02 | 37.51 | ...

Market Performance - The three major indices experienced an increase during the week of August 18 to August 22, with the Shanghai Composite Index rising by 3.49%, the Shenzhen Component Index by 4.57%, and the ChiNext Index by 5.85% [1][2]. Stock Movements - A total of 11 stocks saw a weekly increase of over 40%, with two stocks increasing by more than 60%. Kosen Technology led with a weekly increase of 61.14%, followed by Garden Shares at 61.09%, and Zhen'an Technology at 53.11% [3][4]. - On the downside, 14 stocks experienced a decline of over 15%, with *ST Gaohong leading the drop at 22.67% [3][4]. Trading Activity - 94 stocks had a turnover rate exceeding 100% during the week, with Guangdong Jianke at the top with a turnover rate of 251.47% [5][6]. - The majority of stocks with high turnover rates belonged to the machinery, electronics, and computer sectors [5]. Capital Flow - The machinery sector faced a net outflow of over 18 billion yuan, while the communication, comprehensive, and media sectors saw net inflows [8]. - ZTE Corporation received the highest net inflow of 7.019 billion yuan, with a weekly increase of 32.21% [9]. Institutional Research - A total of 170 listed companies were researched by institutions, with Desai Xiwai receiving the most attention from 228 institutions [12][14]. - The focus of institutional research was primarily on industrial machinery, electronic components, and electrical equipment sectors [12]. New Institutional Interests - 91 stocks were newly favored by institutions, with eight stocks receiving target prices. For instance, Xinqianglian was rated "Overweight" by Huatai Securities with a target price of 42.00 yuan [15][16][17].

Core Viewpoint - The stock of the company experienced significant abnormal fluctuations, with a notable increase in trading volume and turnover rates over a short period [1] Shareholding Structure - As of July 25, 2025, the company's controlling shareholder SWANCOR and two other shareholders hold approximately 85% of the company's A-shares, leaving only about 15% for external circulation [1] Trading Activity - The turnover rates for the company's stock on July 23, 24, and 25, 2025, were 9.50%, 5.44%, and 5.60% respectively, with external circulation turnover rates calculated at approximately 61%, 35%, and 36%, significantly higher than previous levels [1]

Group 1 - The capital market is experiencing a chain reaction, with Shandong Weiming Pharmaceutical Co., Ltd. (referred to as "Weiming Pharmaceutical") announcing significant stock price fluctuations and risk warnings due to abnormal trading activity [1] - Weiming Pharmaceutical expects a net loss attributable to shareholders of 55 million to 85 million yuan for the first half of 2025, representing a year-on-year decline of 85.72% to 187.02% [1] - The crisis is primarily due to the suspension of production and sales by its core subsidiary, Tianjin Weiming Biological Pharmaceutical Co., Ltd. (referred to as "Tianjin Weiming"), following a failure to meet GMP compliance requirements [1] Group 2 - Tianjin Weiming's production and sales of interferon drugs are the main source of revenue for Weiming Pharmaceutical, contributing 60% of the company's revenue in 2024 [2] - In 2024, Tianjin Weiming reported an operating income of 216 million yuan and a net loss of 14.0037 million yuan, significantly impacting Weiming Pharmaceutical's consolidated financial performance [2] - As of now, there are two A-share listed companies in Zibo under other risk warnings (ST), including Weiming Pharmaceutical and Shandong Lianchuang Industrial Development Group Co., Ltd. (referred to as "Lianchuang Shares") [2]